| e1 |
Coalition Forces of Immunologists and Oncologists for Defeating CancerCoalition Forces of Immunologists and Oncologists for Defeating Cancer
Eui-Cheol ShinEui-Cheol Shin
Immune Netw. 2020;20(1):e1. Published online 2020 February 20 DOI: http://dx.doi.org/10.4110/in.2020.20.e1
|
|
| e2 |
Re-defining T-Cell Exhaustion: Subset, Function, and RegulationRe-defining T-Cell Exhaustion: Subset, Function, and Regulation
Se Jin Im, Sang-Jun HaSe Jin Im, Sang-Jun Ha
Immune Netw. 2020;20(1):e2. Published online 2020 February 20 DOI: http://dx.doi.org/10.4110/in.2020.20.e2
|
|
| e3 |
Co-Stimulatory Receptors in Cancers and Their Implications for Cancer ImmunotherapyCo-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
Seongju Jeong, Su-Hyung ParkSeongju Jeong, Su-Hyung Park
Immune Netw. 2020;20(1):e3. Published online 2020 February 7 DOI: http://dx.doi.org/10.4110/in.2020.20.e3
|
|
| e4 |
Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer ImmunotherapyRegulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy
Jung-Ho Kim, Beom Seok Kim, Sang-Kyou LeeJung-Ho Kim, Beom Seok Kim, Sang-Kyou Lee
Immune Netw. 2020;20(1):e4. Published online 2020 February 11 DOI: http://dx.doi.org/10.4110/in.2020.20.e4
|
|
| e5 |
Heterogeneity of Human γδ T Cells and Their Role in Cancer ImmunityHeterogeneity of Human γδ T Cells and Their Role in Cancer Immunity
Hye Won Lee, Yun Shin Chung, Tae Jin KimHye Won Lee, Yun Shin Chung, Tae Jin Kim
Immune Netw. 2020;20(1):e5. Published online 2020 February 14 DOI: http://dx.doi.org/10.4110/in.2020.20.e5
|
|
| e6 |
IL-17-Producing Cells in Tumor Immunity: Friends or Foes?IL-17-Producing Cells in Tumor Immunity: Friends or Foes?
Da-Sol Kuen, Byung-Seok Kim, Yeonseok ChungDa-Sol Kuen, Byung-Seok Kim, Yeonseok Chung
Immune Netw. 2020;20(1):e6. Published online 2020 February 7 DOI: http://dx.doi.org/10.4110/in.2020.20.e6
|
|
| e7 |
Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling AxisFar Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis
Se Jin Oh, Jaeyoon Lee, Yukang Kim, Kwon-Ho Song, Eunho Cho, Minsung Kim, Heejae Jung, Tae Woo KimSe Jin Oh, Jaeyoon Lee, Yukang Kim, Kwon-Ho Song, Eunho Cho, Minsung Kim, Heejae Jung, Tae Woo Kim
Immune Netw. 2020;20(1):e7. Published online 2020 January 20 DOI: http://dx.doi.org/10.4110/in.2020.20.e7
|
|
| e8 |
Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapyPeripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
Kyung Hwan Kim, Chang Gon Kim, Eui-Cheol ShinKyung Hwan Kim, Chang Gon Kim, Eui-Cheol Shin
Immune Netw. 2020;20(1):e8. Published online 2020 February 10 DOI: http://dx.doi.org/10.4110/in.2020.20.e8
|
|
| e9 |
Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint InhibitorsClinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
Juwhan Choi, Sung Yong LeeJuwhan Choi, Sung Yong Lee
Immune Netw. 2020;20(1):e9. Published online 2020 February 17 DOI: http://dx.doi.org/10.4110/in.2020.20.e9
|
|
| e10 |
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future PerspectivesImmunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
Sun Min Lim, Min Hee Hong, Hye Ryun KimSun Min Lim, Min Hee Hong, Hye Ryun Kim
Immune Netw. 2020;20(1):e10. Published online 2020 January 27 DOI: http://dx.doi.org/10.4110/in.2020.20.e10
|
|
| e11 |
Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?
Hye Won Lee, Kyung Joo Cho, Jun Yong ParkHye Won Lee, Kyung Joo Cho, Jun Yong Park
Immune Netw. 2020;20(1):e11. Published online 2020 February 17 DOI: http://dx.doi.org/10.4110/in.2020.20.e11
|
|
